Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-26-000049
Filing Date
2026-08-03
Accepted
2026-08-03 16:02:57
Documents
69
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20260630.htm   iXBRL 10-Q 1324959
2 EX-10.1 exhibit101q22026.htm EX-10.1 88854
3 EX-31.1 exhibit311q22026.htm EX-31.1 19084
4 EX-31.2 exhibit312q22026.htm EX-31.2 18965
5 EX-32.1 exhibit321q22026.htm EX-32.1 10971
  Complete submission text file 0001664710-26-000049.txt   6071313

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20260630.xsd EX-101.SCH 40561
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20260630_cal.xml EX-101.CAL 49439
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20260630_def.xml EX-101.DEF 222563
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20260630_lab.xml EX-101.LAB 537092
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20260630_pre.xml EX-101.PRE 374149
73 EXTRACTED XBRL INSTANCE DOCUMENT kros-20260630_htm.xml XML 601436
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 261232721
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)